View

The Study

Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older Adults.

In simple terms

This study is like a fair test where half the people got a new medicine and half got a sugar pill, and no one knew who got what. After 6 months, they checked everyone's hearts and found no big difference. So we can say the medicine probably didn't hurt their hearts—but we don't know if it helps them either.

76%

Analysis score

76/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting40

Methodology82

Publication100

Statistical77

Study type (basis of the score)

Randomized Controlled Trial

Level 1b - Individual RCT

Critical conflicts of interest — credibility severely compromised

The study was fully funded and conducted by Novartis, with all lead authors employed by Novartis or affiliated with its subsidiaries, and the funder controlled study design, analysis, and interpretation, raising serious concerns that the study serves as industry marketing rather than independent research.

What’s the bottom line?

This drug makes your muscles bigger and fat smaller — but does it hurt your heart?

Where does this study sit?

Systematic Reviews & Meta-analyses

Max 100

Randomized Trials

Max 90

Cohort Studies

Max 72

Case-Control

Max 58

Cross-Sectional

Max 44

Case Reports & Series

Max 30

Expert Opinion

Max 5

StrongerWeaker

Randomized Trials

Level 1b

76 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.

Can establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

1Yes — gaining muscle and losing fat without harming the heart is a big deal, especially for older adults who often lose muscle with age or weight-loss drugs.
2Muscles grew 5.5% bigger, fat dropped 14%, and the heart stayed exactly the same — no change in size or pumping power.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

The Journal of clinical endocrinology and metabolism

Year

2026

Authors

D. Rooks, D. Yates, S. Neelakantham, J. Praestgaard, Ricardo C. Cury, Hildo J. Lamb, R. Roubenoff, O. Pétricoul, E. Lach‐Trifilieff, Eric C. Svensson

Open Access

Analysis v4

DOI:10.1210/clinem/dgag091

PubMed:41873146

View Source

Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.